Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-5.80% $4.19
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 13.30 mill |
EPS: | -20.16 |
P/E: | -0.210 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 3.17 mill |
Avg Daily Volume: | 0.0147 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.210 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.210 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.263 (-93.72%) $-3.93 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 3.76 - 4.54 ( +/- 9.40%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Nijhawan Pardeep | Buy | 5 000 | Common Shares |
2024-03-01 | Nijhawan Pardeep | Buy | 2 765 | Common Shares |
2024-02-01 | Nijhawan Pardeep | Buy | 2 978 | Common Shares |
2024-01-08 | Nijhawan Pardeep | Buy | 2 908 | Common Shares |
2023-08-04 | Lemieux Stephen | Buy | 17 400 | Common Shares |
INSIDER POWER |
---|
75.70 |
Last 96 transactions |
Buy: 2 353 687 | Sell: 309 119 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.19 (-5.80% ) |
Volume | 0.0101 mill |
Avg. Vol. | 0.0147 mill |
% of Avg. Vol | 68.42 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.